GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » Total Liabilities

3SBio, (FRA:YFK) Total Liabilities : €585.3 Mil (As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, Total Liabilities?

3SBio,'s Total Liabilities for the quarter that ended in Dec. 2016 was €585.3 Mil.

3SBio,'s quarterly Total Liabilities increased from Dec. 2015 (€141.63 Mil) to Jun. 2016 (€640.75 Mil) but then declined from Jun. 2016 (€640.75 Mil) to Dec. 2016 (€585.32 Mil).

3SBio,'s annual Total Liabilities declined from Dec. 2014 (€178.60 Mil) to Dec. 2015 (€141.63 Mil) but then increased from Dec. 2015 (€141.63 Mil) to Dec. 2016 (€585.32 Mil).


3SBio, Total Liabilities Historical Data

The historical data trend for 3SBio,'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, Total Liabilities Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.89 11.18 178.60 141.63 585.32

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.60 165.44 141.63 640.75 585.32

3SBio, Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

3SBio,'s Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=156.674+(348.069+80.577
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=585.3

Total Liabilities=Total Assets (A: Dec. 2016 )-Total Equity (A: Dec. 2016 )
=1512.296-926.976
=585.3

3SBio,'s Total Liabilities for the quarter that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=156.674+(348.069+80.577
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=585.3

Total Liabilities=Total Assets (Q: Dec. 2016 )-Total Equity (Q: Dec. 2016 )
=1512.296-926.976
=585.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio, Total Liabilities Related Terms

Thank you for viewing the detailed overview of 3SBio,'s Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines